Breaking New Floor in Cannabinoid Analysis: Brains Bioceutical Corp’s Strong THC Paves the Means for Revolutionary Drug Growth for the pharmaceutical trade.

Brains Bioceutical Corp (“Brains Bio” or the “Firm”), Brains Bio, a pioneer within the cannabinoid-based pharmaceutical trade, is proud to announce a big breakthrough within the journey to a world’s first stable Tetrahydrocannabinol (THC) as an Lively Pharmaceutical Ingredient (API). This milestone displays the corporate’s dedication to innovation and its place on the forefront of the cannabinoid pharmaceutical trade.

“Our stable D9 THC stands as a game-changer within the realm of cannabinoid-based drug growth, providing our pharmaceutical companions an unparalleled instrument to discover new frontiers in drugs. This breakthrough not solely signifies a big development in cannabinoid analysis but additionally underscores our dedication to driving innovation in prescribed drugs.” Ricky Brar CEO & Chairman of Brains Bio. “With this revolutionary know-how, our companions are poised to unlock the complete potential of cannabinoid-based therapies, paving the best way for novel therapies that might rework affected person care. Collectively, we’re devoted to pushing the boundaries of what’s attainable in cannabinoid drugs, with a shared imaginative and prescient of bettering well being outcomes and enhancing high quality of life for sufferers worldwide.”

At Brains Bio, the synergy of a world-class staff, cutting-edge know-how, and strategic trade partnerships has culminated on this groundbreaking achievement. The corporate’s management staff, comprising veterans within the pharmaceutical and biotech industries, has a confirmed observe file of spearheading improvements and navigating complicated regulatory landscapes. This experience has been instrumental in positioning Brains Bio as a frontrunner in cannabinoid-based pharmaceutical growth.

“As a scientist deeply concerned in cannabinoid analysis, I’m thrilled by Brains Bio announcement of the stable D9 THC API. This innovation not solely represents a big leap ahead within the pharmaceutical utility of cannabinoids but additionally underscores the essential want for high-quality, dependable APIs in advancing medical analysis.

“The stable type of THC as an API paves the best way for extra exact dosing, improved stability, and broader utility in drug growth, addressing among the key challenges we face in cannabinoid therapeutics right this moment. It’s a milestone that guarantees to speed up our quest for efficient cannabinoid-based therapies, providing new hope for sufferers worldwide.

“I commend Brains Bioceutical Corp for his or her dedication to excellence and innovation on this quickly evolving discipline.” Dr. Ichiro Takumi, M.D., Ph.D, Chairman of the board of administrators, JCAC (Japan Medical Affiliation of Cannabinoids), Professor of Neurosurgery, St Marianna College College of Medication.

The worldwide hashish prescribed drugs market measurement was valued at USD 1.1 billion in 2022 and is anticipated to develop at a compound annual development fee (CAGR) of 62.5% from 2023 to 2030 [1]. This vital development fee highlights the increasing purposes of hashish in varied medical therapies and the growing acceptance of cannabis-based prescribed drugs within the healthcare trade.

The stable THC API’s market introduction is a transparent indicator of Brains Bio skill to not solely anticipate but additionally form future market developments. The corporate’s forward-thinking strategy is clear in its readiness to fulfill the growing demand for cannabinoid-based prescribed drugs, a sector that continues to point out promising development potential.

To focus on the importance of this milestone, Brains Bio has shipped stable D9 THC samples to researchers and pharmaceutical firms in Asia and South America.

The corporate’s EU GMP-certified services signify the zenith of pharmaceutical manufacturing excellence. These services are the spine of Brains Bio dedication to high quality, security, and efficacy, making certain that this stable D9 THC and different cannabinoid APIs are produced to essentially the most stringent requirements.

This revolutionary product is poised to revolutionize pharmaceutical analysis and remedy choices in varied therapeutic areas, together with ache administration, neurological issues, and psychological well being. The introduction of the stable D9 THC underscores Brains Bio position in pioneering new therapies and enhancing affected person care by scientific discovery.

Brains Bio established relationships with main pharmaceutical organizations throughout the globe is testomony to its fame as a trusted and dependable supply of high-quality cannabinoid-based prescribed drugs. These partnerships are pivotal in advancing medical analysis and creating new therapies, reflecting the corporate’s vital alternatives within the pharmaceutical trade.

The involvement of Brains Bio in groundbreaking medical trials, together with over 30 medical and pre-clinical research, showcases its dedication to scientific rigor and medical development. These trials are essential in exploring the therapeutic efficacy of cannabinoids, additional solidifying the corporate’s place as a pacesetter in science-led cannabinoid-based drug growth.

This pioneering growth is about to draw vital curiosity from key gamers within the pharmaceutical trade, searching for dependable, revolutionary companions within the increasing discipline of cannabinoid drugs. The stable D9 THC isn’t just a product; it’s an emblem of Brains Bio dedication to pioneering the way forward for healthcare and prescribed drugs.